Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 11
Submit an article Journal homepage
81
Views
6
CrossRef citations to date
0
Altmetric
Review

Targeting the retinal microcirculation to treat diabetic sight problems

Raymond M Schiffelers Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands Tel: +31 30 2539392; +31 30 2517839; [email protected]
,
Marcel Ham Fens Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands Tel: +31 30 2539392; +31 30 2517839; [email protected]
,
Janneke M van Blijswijk Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands Tel: +31 30 2539392; +31 30 2517839; [email protected]
,
Dieuwertje I Bink Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands Tel: +31 30 2539392; +31 30 2517839; [email protected]
&
Gert Storm Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Faculty of Science, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands Tel: +31 30 2539392; +31 30 2517839; [email protected]
Pages 1493-1502 | Published online: 26 Oct 2007

Bibliography

  • FAGOT-CAMPAGNA A, BOURDEL-MARCHASSON I, SIMON D: Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab. (2005) 31(Spec. No 2):5S35-35S52.
  • ODEGARD PS, SETTER SM, ILTZ JL: Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. Diabetes Educ. (2006) 32(5):693-712.
  • WHO: Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. (Ed.), WHO document production services, Geneva, Switzerland (2006):46.
  • HARZALLAH F, NCIBI N, ALBERTI H et al.: Clinical and metabolic characteristics of newly diagnosed diabetes patients Diabetes Metab. (2006) 32(6):632-635.
  • SHAH S, IQBAL M, KARAM J, SALIFU M, MCFARLANE SI: Oxidative stress, glucose metabolism, and the prevention of Type 2 diabetes: pathophysiological insights. Antioxid. Redox Signal. (2007) 9(7):911-929.
  • NICOLLS MR, HASKINS K, FLORES SC: Oxidant stress, immune dysregulation, and vascular function in Type I diabetes. Antioxid. Redox Signal. (2007) 9(7):879-889.
  • CUNHA-VAZ J: Characterization and relevance of different diabetic retinopathy phenotypes. Dev. Ophthalmol. (2007) 39:13-30.
  • GIRACH A, VIGNATI L: Diabetic microvascular complications – can the presence of one predict the development of another? J. Diabetes Compl. (2006) 20(4):228-237.
  • JOUSSEN AM, SMYTH N, NIESSEN C: Pathophysiology of diabetic macular edema. Dev. Ophthalmol. (2007) 39:1-12.
  • SJOLIE AK, MOLLER F: Medical management of diabetic retinopathy. Diabet. Med. (2004) 21(7):666-672.
  • KROLL P, RODRIGUES EB, HOERLE S: Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica (2007) 221(2):78-94.
  • TSILIBARY EC: Microvascular basement membranes in diabetes mellitus. J. Pathol. (2003) 200(4):537-546.
  • URATA Y, YAMAGUCHI M, HIGASHIYAMA Y et al.: Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic. Biol. Med. (2002) 32(8):688-701.
  • CRABBE MJ, GOODE D: Aldose reductase: a window to the treatment of diabetic complications? Prog. Retin. Eye Res. (1998) 17(3):313-383.
  • TODA N, NAKANISHI-TODA M: Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog. Retin. Eye Res. (2007) 26(3):205-238.
  • WAY KJ, KATAI N, KING GL: Protein kinase C and the development of diabetic vascular complications. Diabet. Med. (2001) 18(12):945-959.
  • SHIN S, KU YH, HO JX et al.: Progressive impairment of erythrocyte deformability as indicator of microangiopathy in Type 2 diabetes mellitus. Clin. Hemorheol. Microcirc. (2007) 36(3):253-261.
  • NEGREAN V, SUCIU I, SAMPELEAN D, COZMA A: Rheological changes in diabetic microangiopathy. Rom. J. Intern. Med. (2004) 42(2):407-413.
  • CHIARELLI F, SANTILLI F, MOHN A: Role of growth factors in the development of diabetic complications. Horm. Res. (2000) 53(2):53-67.
  • SILVA KC, PINTO CC, BISWAS SK et al.: Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. Exp. Eye Res. (2007).
  • ADLER AI: Treating high blood pressure in diabetes: the evidence. Semin. Vasc. Med. (2002) 2(2):127-137.
  • ONG HT, CHEAH JS: Choice of antihypertensive drug in the diabetic patient. Med. Gen. Med. (2005) 7(2):74.
  • PATEL A, CHALMERS J, POULTER N: ADVANCE: action in diabetes and vascular disease. J. Hum. Hypertens. (2005) 19(Suppl. 1):S27-S32.
  • CASAS JP, CAVALLERI GL, BAUTISTA LE et al.: Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol. (2006) 164(10):921-935.
  • DEMAINE AG: Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr. Med. Chem. (2003) 10(15):1389-1398.
  • CHUNG SS, CHUNG SK: Genetic analysis of aldose reductase in diabetic complications. Curr. Med. Chem. (2003) 10(15):1375-1387.
  • LIU L, YU Q, WANG H et al.: Association of intercellular adhesion molecule 1 polymorphisms with retinopathy in Chinese patients with Type 2 diabetes. Diabet. Med. (2006) 23(6):643-648.
  • MA J, MOLLSTEN A, PRAZNY M et al.: Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy. Diabet. Med. (2006) 23(10):1093-1099.
  • HU CJ, WANG CH, LEE JH et al.: Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area. Clin. Chem. Lab. Med. (2007) 45(1):20-25.
  • HADJADJ S, TARNOW L, FORSBLOM C et al.: Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J. Am. Soc. Nephrol. (2007) 18(4):1284-1291.
  • YAMADA N, HORIKAWA Y, ODA N et al.: Genetic variation in the hypoxia-inducible factor-1α gene is associated with Type 2 diabetes in Japanese. J. Clin. Endocrinol. Metab. (2005) 90(10):5841-5847.
  • SUGANTHALAKSHMI B, ANAND R, KIM R et al.: Association of VEGF and eNOS gene polymorphisms in Type 2 diabetic retinopathy. Mol. Vis. (2006) 12:336-341.
  • DEL BO R, SCARLATO M, GHEZZI S et al.: VEGF gene variability and Type 1 diabetes: evidence for a protective role. Immunogenetics (2006) 58(2-3):107-112.
  • BROSIUS FC, HEILIG CW: Glucose transporters in diabetic nephropathy. Pediatr. Nephrol. (2005) 20(4):447-451.
  • VISCHER UM: von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J. Thromb. Haemost. (2006) 4(6):1186-1193.
  • CONSTANS J, CONRI C: Circulating markers of endothelial function in cardiovascular disease. Clin. Chim. Acta (2006) 368(1-2):33-47.
  • UCGUN NI, YILDIRIM Z, KILIC N, GURSEL E: The importance of serum lipids in exudative diabetic macular edema in Type 2 diabetic patients. Ann. NY Acad. Sci. (2007) 1100:213-217.
  • LUDWIG S, SHEN GX: Statins for diabetic cardiovascular complications. Curr. Vasc. Pharmacol. (2006) 4(3):245-251.
  • CUSICK M, CHEW EY, CHAN CC et al.: Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology (2003) 110(11):2126-2133.
  • PEDERSEN O, GAEDE P: Intensified multifactorial intervention and cardiovascular outcome in Type 2 diabetes: the Steno-2 study. Metabolism (2003) 52(8 Suppl. 1):19-23.
  • VINIK AI, VINIK E: Prevention of the complications of diabetes. Am. J. Manag. Care (2003) 9(3 Suppl.):S63-S80; quiz S81-S64.
  • LANG GE: Pharmacological treatment of diabetic retinopathy. Ophthalmologica (2007) 221(2):112-117.
  • POULAKI V, QIN W, JOUSSEN AM et al.: Acute intensive insulin therapy exacerbates diabetic blood–retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J. Clin. Invest. (2002) 109(6):805-815.
  • PICKERING TG: Cardiorenal protection in diabetes. Heart Dis. (2000) 2(2):S18-S22.
  • SCHRIER RW: Treating high-risk diabetic hypertensive patients with comorbid conditions. Am. J. Kidney Dis. (2000) 36(3 Suppl. 1):S10-S17.
  • SJOLIE AK: Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res. Clin. Pract. (2007) 76(Suppl. 1):S31-S39.
  • NEUBAUER AS, ULBIG MW: Laser treatment in diabetic retinopathy. Ophthalmologica (2007) 221(2):95-102.
  • HELBIG H: Surgery for diabetic retinopathy. Ophthalmologica (2007) 221(2):103-111.
  • JAKUS V, RIETBROCK N: Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. (2004) 53(2):131-142.
  • BOLTON WK, CATTRAN DC, WILLIAMS ME et al.: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. (2004) 24(1):32-40.
  • KHALIFAH RG, CHEN Y, WASSENBERG JJ: Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann. NY Acad. Sci. (2005) 1043:793-806.
  • MENE P, FESTUCCIA F, PUGLIESE F: Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus. Am. J. Cardiovasc. Drugs (2003) 3(5):315-320.
  • BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813-820.
  • BABAEI-JADIDI R, KARACHALIAS N, AHMED N, BATTAH S, THORNALLEY PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes (2003) 52(8):2110-2120.
  • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet (2000) 355(9200):253-259.
  • MAYER-DAVIS EJ, BELL RA, REBOUSSIN BA et al.: Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley diabetes study. Ophthalmology (1998) 105(12):2264-2270.
  • HAMMES HP, BARTMANN A, ENGEL L, WULFROTH P: Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia (1997) 40(6):629-634.
  • VICTOR VM, ROCHA M: Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr. Pharm. Des. (2007) 13(8):845-863.
  • LIN J, BIERHAUS A, BUGERT P et al.: Effect of R-(+)-α-lipoic acid on experimental diabetic retinopathy. Diabetologia (2006) 49(5):1089-1096.
  • YABE-NISHIMURA C: Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. (1998) 50(1):21-33.
  • SRIVASTAVA SK, RAMANA KV, BHATNAGAR A: Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. (2005) 26(3):380-392.
  • PFEIFER MA, SCHUMER MP, GELBER DA: Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes (1997) 46(Suppl. 2):S82-S89.
  • GABBAY KH: Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Curr. Diab. Rep. (2004) 4(6):405-408.
  • BRIL V, BUCHANAN RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care (2006) 29(1):68-72.
  • GIANNOUKAKIS N: Drug evaluation: ranirestat – an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr. Opin. Investig. Drugs (2006) 7(10):916-923.
  • NEGORO T, MURATA M, UEDA S et al.: Novel, highly potent aldose reductase inhibitors: (R)-(-)-2(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a] pyrazine-4-spiro-3´-pyrrolidine-1,2´,3,5´-tetrone (AS-3201) and its congeners. J. Med. Chem. (1998) 41(21):4118-4129.
  • ZOTOVA EG, CHRIST GJ, ZHAO W et al.: Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats. J. Diabetes Compl. (2007) 21(3):187-195.
  • HOTTA N, AKANUMA Y, KAWAMORI R et al.: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care (2006) 29(7):1538-1544.
  • SUN W, OATES PJ, COUTCHER JB, GERHARDINGER C, LORENZI M: A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes (2006) 55(10):2757-2762.
  • Ruboxistaurin: LY 333531. Drugs R&D (2007) 8(3):193-199.
  • GARDNER TW, ANTONETTI DA: Ruboxistaurin for diabetic retinopathy. Ophthalmology (2006) 113(12):2135-2136.
  • AIELLO LP, DAVIS MD, GIRACH A et al.: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology (2006) 113(12):2221-2230.
  • FUNATSU H, YAMASHITA H: Pathophysiology of diabetic retinopathy. Drug News Perspect. (2002) 15(10):633-639.
  • CAMPOCHIARO PA: Ocular neovascularisation and excessive vascular permeability. Expert Opin. Biol. Ther. (2004) 4(9):1395-1402.
  • MARNEROS AG, OLSEN BR: Physiological role of collagen XVIII and endostatin. FASEB J. (2005) 19(7):716-728.
  • CAMPOCHIARO PA: Gene therapy for ocular neovascularization. Curr. Gene Ther. (2007) 7(1):25-33.
  • NOMA H, FUNATSU H, YAMASHITA H et al.: Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol. (2002) 120(8):1075-1080.
  • WAHL ML, MOSER TL, PIZZO SV: Angiostatin and anti-angiogenic therapy in human disease. Recent Prog. Horm. Res. (2004) 59:73-104.
  • SIMA J, ZHANG SX, SHAO C, FANT J, MA JX: The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett. (2004) 564(1-2):19-23.
  • KADERLI B, AVCI R, GELISKEN O, YUCEL AA: Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO. Int. Ophthalmol. (2005) 26(6):207-214.
  • KUPPERMANN BD, BLUMENKRANZ MS, HALLER JA et al.: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. (2007) 125(3):309-317.
  • IIDA T: Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema? Br. J. Ophthalmol. (2007) 91(4):407-408.
  • BANCIU M, SCHIFFELERS RM, FENS MH, METSELAAR JM, STORM G: Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J. Control. Rel. (2006) 113(1):1-8.
  • ARJAMAA O, NIKINMAA M: Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. (2006) 83(3):473-483.
  • XIAO Q, ZENG S, LING S, LV M: Up-regulation of HIF-1α and VEGF expression by elevated glucose concentration and hypoxia in cultured human retinal pigment epithelial cells. J. Huazhong Univ. Sci. Technol. Med. Sci. (2006) 26(4):463-465.
  • BEPPU K, NAKAMURA K, LINEHAN WM, RAPISARDA A, THIELE CJ: Topotecan blocks hypoxia-inducible factor-1α and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. (2005) 65(11):4775-4781.
  • KLAUSMEYER P, MCCLOUD TG, MELILLO G et al.: Identification of a new natural camptothecin analogue in targeted screening for HIF-1α inhibitors. Planta Med. (2007) 73(1):49-52.
  • BELOZEROV VE, VAN MEIR EG: Inhibitors of hypoxia-inducible factor-1 signaling. Curr. Opin. Investig. Drugs (2006) 7(12):1067-1076.
  • PATIAR S, HARRIS AL: Role of hypoxia-inducible factor-1α as a cancer therapy target. Endocr. Relat. Cancer (2006) 13(Suppl. 1):S61-S75.
  • NAGASAWA H, UTO Y, KIRK KL, HORI H: Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol. Pharm. Bull. (2006) 29(12):2335-2342.
  • BRAHIMI-HORN MC, POUYSSEGUR J: Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem. Pharmacol. (2007) 73(3):450-457.
  • CHIARELLI F, GIANNINI C, DI MARZIO D, MOHN A: Treating diabetic retinopathy by tackling growth factor pathways. Curr. Opin. Investig. Drugs (2005) 6(4):395-409.
  • MOREIRA IS, FERNANDES PA, RAMOS MJ: Vascular endothelial growth factor (VEGF) inhibition – a critical review. Anticancer Agents Med. Chem. (2007) 7(2):223-245.
  • STARITA C, PATEL M, KATZ B, ADAMIS AP: Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev. Ophthalmol. (2007) 39:122-148.
  • CAMPOCHIARO PA: Molecular targets for retinal vascular diseases. J. Cell Physiol. (2007) 210(3):575-581.
  • ADAMIS AP, ALTAWEEL M, BRESSLER NM et al.: Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2006) 113(1):23-28.
  • PATTERSON DM, RUSTIN GJ: Vascular DAMAGING agents. Clin. Oncol. (R. Coll. Radiol.) (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.